Erika P. Hamilton, MD
Director, Breast Cancer and Gynecologic Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology
Dr. Hamilton serves as the director of breast cancer and gynecologic cancer research for Sarah Cannon Research Institute (SCRI) at Tennessee Oncology, and cares for patients facing breast and gynecologic cancer. In Dr. Hamilton’s role, she oversees the program and the clinical trial menu for these cancers across the SCRI network.
Dr. Hamilton joined SCRI in 2013 as an investigator in drug development for women’s cancers, and has served as director of breast cancer and gynecologic cancer research since 2015. Her mother was diagnosed with breast cancer when Dr. Hamilton was in middle school, and thankfully is a survivor. Dr. Hamilton is passionate about personalized treatment, empowering her patients, and treating each person individually based on their goals and preferences.
Dr. Hamilton received her undergraduate degree from Washington and Lee University in Virginia and received a NCAA Postgraduate Scholarship. She then completed her medical degree and residency from University of North Carolina in Chapel Hill and fellowship training in hematology and oncology at Duke University, where she was recognized as a Top 5 Finalist for Duke's Annual House staff Fellow Teaching Award.
Dr. Hamilton was named to the Women to Watch Class of 2021 for Nashville Medical News. She was selected for the American Society of Clinical Oncology’s (ASCO) Leadership Development Class for 2021-2022, and was the past chair of ASCO’s Scientific Committee for Metastatic Breast Cancer for 2019-2020. She is the 2023-2025 Scientific Committee co-chair of the ESMO Breast Cancer Meeting, serves on ASCO’s Cancer Research Committee, and is an associate editor for Clinical Breast Cancer.
Dr. Hamilton is board certified in internal medicine and oncology. Additionally, she is a partner with Tennessee Oncology, PLLC.